No Data
No Data
Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
Express News | IDEAYA Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide161 in Combination With Keytruda® (Pembrolizumab) in Patients With Endometrial Cancer
IDEAYA Biosciences Nominates IDE892 as Development Candidate
Express News | IDEAYA Biosciences Inc -Ind-Enabling Studies Ongoing and Targeting Ind-Filing for Ide892 in Mid-2025
Express News | IDEAYA Biosciences Announces Development Candidate Nomination of Ide892, a Potential Best-in-Class Mta-Cooperative Prmt5 Inhibitor